Treatments for COVID-19: emerging drugs against the coronavirus - reply

Main Article Content

Francesco Potì


COVID-19, emerging drugs, reply




Download data is not yet available.
Abstract 285 | PDF Downloads 337


1. Potì F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for covid-19: Emerging drugs against the coronavirus. Acta Biomed. 2020;91(2):118-136. doi:10.23750/abm.v91i2.9639
2. de Haan CAM, Rottier PJM. Molecular Interactions in the Assembly of Coronaviruses. Adv Virus Res. 2005;64:165-230. doi:10.1016/S0065-3527(05)64006-7
3. de Wilde AH, Wannee KF, Scholte FEM, et al. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. J Virol. 2015;89(16):8318-8333. doi:10.1128/jvi.01029-15
4. Rodrigo R. R. D, Dennis C. CJ, Luis P. I, Jez L. M, Douglas F. N, Timothy R. P. Repurposing FDA-Approved Drugs for COVID-19 Using a Data-Driven Approach. chemRxiv. April 2020. doi:10.26434/chemrxiv.12148764.v1
5. Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012-10017. doi:10.1073/pnas.0403596101
6. Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. 2016;2016(12). doi:10.1002/14651858.CD007655.pub3
7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;2018(4). doi:10.1002/14651858.CD001841.pub3
8. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. In: Journal of Cardiovascular Pharmacology. Vol 27. Lippincott Williams and Wilkins; 1996. doi:10.1097/00005344-199627003-00007

Most read articles by the same author(s)